IRVINE, Calif. — June 28, 2024 — Immunis, Inc., a private biotechnology company developing regenerative secretomes for age and disease-related immune dysfunction, is delighted to welcome Dr. Christina Weng as its newest Advisory Board member. Dr. Weng is an accomplished physician-scientist, entrepreneur, and biotech executive. She is a board-certified dermatologist at the Massachusetts General Hospital and faculty at Harvard Medical School. An expert in regenerative medicine, she currently serves as the Chief Medical Officer of Pelage Pharmaceuticals, which targets stem cell metabolism to address hair loss.

As former Head of Business Development & Strategy of Kira Pharmaceuticals, Dr. Weng’s extensive experience can support Immunis’ evolving corporate startup strategy. Her prior role as Chief Strategy Officer and co-founder of Mymiel, a high-performance clean skincare line, will facilitate Immunis’ efforts of eventually bringing IMMUNA to market. Dr. Weng is also on the Board of Directors for the Dermatology Innovation Forum and Dermatology Summit, which aligns with Immunis’ ongoing preclinical research investigating IMMUNA for wound healing.

“We are in a golden age for regenerative medicine” says Dr. Weng. “Immunis stands out with its strong scientific foundation that brings a novel multi-component approach to age-related dysfunction spanning multiple organ systems. I am excited to work with this world-class team to advance the clinical programs and transform the way we think about solutions for age-related decline.“

Her impressive academic record includes an undergraduate degree from the California Institute of Technology, MD Magna Cum Laude from Harvard, and a dermatology residency, postdoctoral training, and fellowship at Harvard. Immunis is very fortunate to have a brilliant mind with a diversified medical and corporate skillset guiding the team.

About Immunis Inc.
Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/

Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.

Contact email: contact@immunisbiomedical.com